唑来膦酸对原发性骨质疏松症患者骨痛和骨密度的作用  

Effect of zoledronic acid on primary osteoporosis in the treatment of bone pain and bone mineral density

作　　者：金国华[1] 赵胜春[1] 陈欣[1] 陈红卫[1] 李军[1] 潘月好 JIN Guo-hua;ZHAO Sheng-chun;CHEN Xin;CHEN Hong-wei;LI Jun;PAN Yue-hao(Department of Orthopedics, Yiwu Central Hospital, Zhejiang Province, Yiwu 322000, China)

机构地区：[1]浙江省义乌市中心医院骨科,浙江义乌322000

出　　处：《中国生化药物杂志》2017年第11期210-211,共2页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的探讨原发性骨质疏松症患者采用唑来膦酸的治疗效果。方法回顾性分析浙江省义乌市中心医院2016年2月～2017年5月收治的160例原发性骨质疏松症患者的诊治情况，其中采用口服钙尔奇D、阿仑膦酸钠为对照组，采用唑来膦酸、口服钙尔奇D治疗为观察组。分别于治疗前、后评价2组患者腰背部疼痛情况，检测2组腰椎（L1-3）、髋部骨密度。记录治疗期间不良反应。结果治疗后，2组患者腰背部疼痛评分明显低于治疗前，且观察组腰背部疼痛评分低于对照组（P＜0.05）；2组患者治疗后腰椎（L1-3）、髋部骨密度明显高于治疗前，且观察组治疗后腰椎（L1-3）、髋部骨密度明显高于对照组（P＜0.05）。2组不良反应率相比较差异无统计学意义。结论采用唑来膦酸治疗原发性骨质疏松症可有利于提高其骨密度，缓解其疼痛，且具有一定安全性。Objective To investigate the efficacy of zoledronic acid in patients with primary osteoporosis.Methods We retrospectively analyzed the diagnosis and treatment of160patients with primary osteoporosis in the hospital from February2016to May2017.The patients were treated with oral calcium Erqi D and alendronate as the control group,and treated with zoledronic acid and oral calcium as observation group.The lumbar spine(L1-3)and hip bone mineral density were measured before and after treatment.Results the adverse reactions during treatment.Results The bone density of lumbar vertebrae(L1-3)and hip was significantly higher than that of the control group(P<0.05).The pain score of the two groups was significantly lower than that of the before treatment(P<0.05).The bone density of the lumbar vertebrae(L1-3)and the hip bone were significantly higher than those in the control group(P<0.05).The differences of adverse reactionsbetween two groups was not significant.Conclusion The use of zoledronic acid in the treatment of primary osteoporosis may be beneficial to improve its bone density,relieve its pain,and has a certain safety.

关 键 词：骨密度 唑来膦酸 原发性骨质疏松症 钙尔奇D 阿仑膦酸钠 

分 类 号：R580[医药卫生—内分泌]